A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
University of Missouri researchers released PSBench, a database of 1.4 million annotated protein structure models verified by independent experts. The resource aims to improve AI assessment of protein models as biologic drug discovery moves toward data-driven design.
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Protein biomarkers and self-sampling methods are transforming drug development and occupational health surveillance, enabling more efficient clinical trials, improved target selection, and minimally invasive continuous monitoring.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.
